Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy.

Journal Article (Journal Article;Review)

INTRODUCTION: The first patients with Coronavirus disease 2019 (COVID-19) emerged at the end of 2019. This novel viral infection demonstrated unique features that include prothrombotic clinical presentations. However, one year after the first occurrence, there remain many unanswered questions. We tried to address some of the important queries in this review. AREAS COVERED: We raised the following critical questions. 'Why is COVID-19 so hypercoagulable?', 'Why are most coagulation test results relatively normal?', 'Why is COVID-19-associated coagulopathy more thrombotic than most other infectious diseases?', 'Why is arterial thrombus formed frequently?', 'Is anticoagulant therapy for COVID-19 effective?', and 'Are there racial disparities in thrombosis in COVID-19?' EXPERT OPINION: There are commonalities and differences in the pathogeneses and clinical features between COVID-19 and other infectious diseases. Correct understanding will help discussing appropriate anticoagulation prophylaxis or treatment for thromboembolism.

Full Text

Duke Authors

Cited Authors

  • Iba, T; Levy, JH; Connors, JM; Warkentin, TE; Thachil, J; Levi, M

Published Date

  • August 2021

Published In

Volume / Issue

  • 15 / 8

Start / End Page

  • 1003 - 1011

PubMed ID

  • 33667146

Electronic International Standard Serial Number (EISSN)

  • 1747-6356

Digital Object Identifier (DOI)

  • 10.1080/17476348.2021.1899815


  • eng

Conference Location

  • England